The latest price target for NRX Pharmaceuticals (NASDAQ:NRXP) was reported by EF Hutton on October 30, 2024. The analyst firm set a price target for $31.00 expecting NRXP to rise to within 12 months (a possible 2572.41% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for NRX Pharmaceuticals (NASDAQ:NRXP) was provided by EF Hutton, and NRX Pharmaceuticals maintained their buy rating.

There is no last upgrade for NRX Pharmaceuticals

There is no last downgrade for NRX Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NRX Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NRX Pharmaceuticals was filed on October 30, 2024 so you should expect the next rating to be made available sometime around October 30, 2025.

While ratings are subjective and will change, the latest NRX Pharmaceuticals (NRXP) rating was a maintained with a price target of $31.00 to $31.00. The current price NRX Pharmaceuticals (NRXP) is trading at is $1.16, which is out of the analyst’s predicted range.